This inventor holds 2 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2022-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2026
Title: Norio Oyabu: Innovator in AMPA Receptor Function Enhancement
Introduction
Norio Oyabu is a notable inventor based in Kanagawa, Japan. He has made significant contributions to the field of pharmacology, particularly in the development of compounds that enhance AMPA receptor function. His work is expected to have a profound impact on the treatment of various neurological disorders.
Latest Patents
Norio Oyabu holds a patent for "Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function." This invention aims to provide a heterocyclic compound that exhibits an AMPA receptor potentiator effect. The compound is anticipated to be useful as an agent for the prophylaxis or treatment of conditions such as depression, Alzheimer's disease, schizophrenia, and attention deficit hyperactivity disorder (ADHD). The patent details a compound represented by a specific formula, including its salts.
Career Highlights
Norio Oyabu is associated with Takeda Pharmaceutical Company Limited, a leading global pharmaceutical company. His work at Takeda has allowed him to focus on innovative solutions for complex health issues. His dedication to research and development has positioned him as a key figure in his field.
Collaborations
Norio Oyabu has collaborated with esteemed colleagues, including Shinji Nakamura and Satoshi Mikami. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in pharmacology.
Conclusion
Norio Oyabu's contributions to the enhancement of AMPA receptor function represent a significant advancement in the treatment of neurological disorders. His innovative work continues to inspire future research and development in the pharmaceutical industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
